Stockscreener 앱 받기
52.53
4.75%
-2.55
시간 외 거래:
52.53
Alkermes Plc 주식(ALKS)의 최신 뉴스
ALKS Maintained by Wells Fargo -- Price Target Raised to $65.00 - GuruFocus
ALKS Downgraded by B of A Securities -- Rating Changed to Underp - GuruFocus
BofA downgrades Alkermes stock rating on valuation concerns - Investing.com
REGBlackRock GroupSAR 6ALKERMES PLC - TradingView
Enterprise value to EBIT forward of Alkermes plc – NASDAQ:ALKS - TradingView
Price to sales forward of Alkermes plc – NASDAQ:ALKS - TradingView
ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes - Stocktwits
Alkermes plummets on mid-stage Alixorexton data for narcolepsy - MSN
Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda - BioPharma Dive
What Does the Recent Insider Sale by Alkermes' VP of Finance Signify - Kavout | AI
Alkermes Public Limited Company Actuals & Estimates (NASDAQ:ALKS) - TradingView
ALKS Forecast — Price Target — Prediction for 2027 - TradingView
Alkermes stock hits 52-week high at 51.77 USD - Investing.com
Alkermes stock hits 52-week high at 51.77 USD By Investing.com - Investing.com India
Liquidity Mapping Around (ALKS) Price Events - Stock Traders Daily
Alkermes Jumps 6.9% After Needham Maintains Buy - AlphaStreet
ALKS Maintained by Needham -- Price Target Raised to $61.00 - GuruFocus
Alkermes PLC (ALKS) Shares Surge 4.3% -- What GF Score of 70 Tel - GuruFocus
ALKS Maintained by TD Cowen -- Price Target Raised to $50 - GuruFocus
Alkermes Plc (ALKS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ALKS News | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
Alkermes plc (ALKS) Stock Analysis: Navigating Growth in Biopharmaceuticals with a 4.88% Upside - DirectorsTalk Interviews
Alkermes presents detailed positive results from Vibrance-2 phase 2 study of Alixorexton in adults with narcolepsy type 2 at SLEEP 2026 - MSN
Alkermes announces orphan drug designations for Alixorexton in the US and Europe - MSN
Alkermes: "Buy" On Avadel Acquisition And Positive NT2 Data With Alixorexton (NASDAQ:ALKS) - Seeking Alpha
Did Positive Vibrance-2 Data for Alixorexton Just Shift Alkermes' (ALKS) Investment Narrative? - simplywall.st
Alkermes stock hits 52-week high at 45.76 USD By Investing.com - Investing.com India
Alkermes stock hits 52-week high at 45.76 USD - Investing.com
Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Alkermes (ALKS): Piper Sandler Lowers Price Target, Maintains Ov - GuruFocus
Alkermes (ALKS) Study Results Highlight Potential Benefits for N - GuruFocus
Needham raises Alkermes stock price target on narcolepsy drug data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Alkermes stock rating on trial data By Investing.com - Investing.com South Africa
Needham raises Alkermes stock price target on narcolepsy drug data - Investing.com
H.C. Wainwright reiterates Alkermes stock rating on trial data - Investing.com
ALKS Maintains Buy Rating by Needham -- Price Target Raised to $54.00 - GuruFocus
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026 - BioSpace
Alkermes Plc (ALKS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alkermes Plc (ALKS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alkermes Plc (ALKS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Alkermes Plc (ALKS) Institutional Confidence - TradingKey
Alkermes Plc (ALKS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alkermes (ALKS) Shares Fall 31% Despite Positive Phase 2 Trial R - GuruFocus
Alkermes (ALKS) Advances Narcolepsy Treatment with Positive Phas - GuruFocus
Alkermes reports positive phase 2 results for narcolepsy drug By Investing.com - Investing.com India
Alkermes Plc (ALKS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alkermes Plc (ALKS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alkermes reports positive phase 2 results for narcolepsy drug - Investing.com
Alkermes Plc (ALKS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Alkermes stock jumps as narcolepsy drug hits trial goals By Investing.com - Investing.com South Africa
0.61%
3.28%
자본화:
|
볼륨(24시간):